Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term radiation-therapy. Found 120 abstracts

no pagination
Shaikh T, Meyer JE, Horwitz EM. Optimal Use of Combined Modality Therapy in the Treatment of Esophageal Cancer. Surg Oncol Clin N Am. 2017 Jul;26(3):405-29.   PMCID: REVIEW
Allen AM, Pawlicki T, Dong L, Fourkal E, Buyyounouski M, Cengel K, Plastaras J, Bucci MK, Yock TI, Bonilla L, Price R, Harris EE, Konski AA, Stinseymour M. An evidence based review of proton beam therapy: The report of ASTRO's emerging technology committee. Radiotherapy and Oncology. 2012 Apr;103(1):8-11.   PMCID: not NIH funded
Buyyounouski MK, Davis BJ, Prestidge BR, Shanahan TG, Stock RG, Grimm PD, Demanes DJ, Zaider M, Horwitz EM. A survey of current clinical practice in permanent and temporary prostate brachytherapy: 2010 update. Brachytherapy. 2012 Jul;11(4):299-305.   PMCID: Not NIH funded
Buyyounouski MK, Pickles T, Kestin LL, Allison R, Williams SG. Validating the Interval to Biochemical Failure for the Identification of Potentially Lethal Prostate Cancer. Journal of Clinical Oncology. 2012 May;30(15):1857-63.   PMCID: not NIH funded
Hossain M, Schirmer T, Richardson T, Chen LL, Buyyounouski MK, Ma CM. Effect of Gold Marker Seeds on Magnetic Resonance Spectroscopy of the Prostate. International Journal of Radiation Oncology Biology Physics. 2012 May;83(1):451-8.   PMCID: not NIH funded
Keller LM, Buyyounouski MK, Sopka D, Ruth K, Klayton T, Pollack A, Watkins-Bruner D, Greenberg R, Price R, Horwitz EM. Stamp Test Delivers Message on Erectile Dysfunction After High-dose Intensity-modulated Radiotherapy for Prostate Cancer. Urology. 2012 Aug;80(2):337-42.   PMCID: PMCID:PMC3461589[Available on 2013/8/1]
Klayton T, Price R, Buyyounouski MK, Sobczak M, Greenberg R, Li JS, Keller L, Sopka D, Kutikov A, Horwitz EM. Prostate Bed Motion During Intensity-Modulated Radiotherapy Treatment. International Journal of Radiation Oncology Biology Physics. 2012 Sep;84(1):130-6.   PMCID: PMC3285397
Martins RG, D'Amico TA, Loo BW, Pinder-Schenck M, Borghaei H, Chaft JE, Ganti AK, Kong FM, Kris MG, Lennes IT, Wood DE. The Management of Patients With Stage IIIA Non-Small Cell Lung Cancer With N2 Mediastinal Node Involvement. Journal of the National Comprehensive Cancer Network. 2012 May;10(5):599-613.   PMCID: not NIH funded
Mohler JL, Armstrong AJ, Bahnson RR, Boston B, Busby JE, D'Amico AV, Eastham JA, Enke CA, Farrington T, Higano CS, Horwitz EM, Kantoff PW, Kawachi MH, Kuettel M, Lee RJ, MacVicar GR, Malcolm AW, Miller D, Plimack ER, Pow-Sang JM, Roach M, Rohren E, Rosenfeld S, Srinivas S, Strope SA, Tward J, Twardowski P, Walsh PC, Ho M, Shead DA. Prostate Cancer, Version 3.2012 Featured Updates to the NCCN Guidelines. Journal of the National Comprehensive Cancer Network. 2012 Sep;10(9):1081-7.   PMCID: Not NIH Funded
Pfister DG, Ang KK, Brizel DM, Burtness B, Cmelak AJ, Colevas AD, Dunphy F, Eisele DW, Gilbert J, Gillison ML, Haddad RI, Haughey BH, Hicks WL, Hitchcock YJ, Kies MS, Lydiatt WM, Maghami E, Martins R, McCaffrey T, Mittal BB, Pinto HA, Ridge JA, Samant S, Sanguineti G, Schuller DE. Mucosal Melanoma of the Head and Neck. Journal of the National Comprehensive Cancer Network. 2012 Mar;10(3):320-38.   PMCID: not NIH Funded
Rich TA, Winter K, Safran H, Hoffman JP, Erickson B, Anne PR, Myerson RJ, Cline-Burkhardt VJ, Perez K, Willett C. Weekly paclitaxel, gemcitabine, and external irradiation followed by randomized farnesyl transferase inhibitor R115777 for locally advanced pancreatic cancer. Oncotargets and Therapy. 2012 Jan;5:161-70.   PMCID: PMC3430391
Thomay AA. Nonsurgical Adjunctive Treatment and Its Effects on the Axilla. Current Problems in Cancer. 2012 Sep;36(5):305-24.   PMCID: not NIH funded
Turaka A, Buyyounouski MK, Hanlon AL, Horwitz EM, Greenberg RE, Movsas B. Hypoxic Prostate/Muscle PO2 Ratio Predicts for Outcome in Patients With Localized Prostate Cancer: Long-Term Results. International Journal of Radiation Oncology Biology Physics. 2012 Mar;82(3):E433-E439.   PMCID: not NIH funded
Wilder RB, Buyyounouski MK, Efstathiou JA, Beard CJ. Radiotherapy Treatment Planning for Testicular Seminoma. International Journal of Radiation Oncology Biology Physics. 2012 Jul;83(4):E445-E452.   PMCID: not NIH funded
Boorjian SA, Karnes RJ, Viterbo R, Rangel LJ, Bergstralh EJ, Horwitz EM, Blute ML, Buyyounouski MK. Long-Term Survival After Radical Prostatectomy Versus External-Beam Radiotherapy for Patients With High-Risk Prostate Cancer. Cancer. 2011 Jul;117(3):2883-91.   PMCID: PMC3139725
Hoppe RT, Advani RH, Ai WY, Ambinder RF, Bello CM, Bierman PJ, Blum KA, Dabaja B, Duron Y, Forero A, Gordon LI, Hernandez-Ilizaliturri FJ, Hochberg EP, Maloney DG, Mansur D, Mauch PM, Metzger M, Moore JO, Morgan D, Moskowitz CH, Poppe M, Pro B, Weiss L, Winter JN, Yahalom J, Nccn Clinical Practice Guidelines, Rbone Pp VP, Nellos Gp VP, Nellos Gp VP. NCCN Clinical Practice Guidelines in Oncology for Hodgkin Lymphoma. Journal of the National Comprehensive Cancer Network. 2011 Sep;9(9):1020-58.   PMCID: not NIH funded
Bonner JA, Harari PM, Giralt J, Cohen RB, Jones CU, Sur RK, Raben D, Baselga J, Spencer SA, Zhu JM, Youssoufian H, Rowinsky EK, Ang KK. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncology. 2010 Jan;11(1):21-8.   PMCID: not NIH funded
Demetri GD, Antonia S, Benjamin RS, Bui MM, Casper ES, Conrad EU, DeLaney TF, Ganjoo KN, Heslin MJ, Hutchinson RJ, Kane JM, Letson GD, McGarry SV, O'Donnell RJ, Paz IB, Pfeifer JD, Pollock RE, Randall RL, Riedel RF, Schupak KD, Schwartz HS, Thornton K, von Mehren M, Wayne J. Soft Tissue Sarcoma. Journal of the National Comprehensive Cancer Network. 2010 Jun;8(6):630-74.   PMCID: not NIH funded
Hoffman JP. Status of Neoadjuvant Therapy for Resectable Pancreatic Cancer. Surgical Oncology Clinics of North America. 2010 Apr;19(2):411-+.   PMCID: not NIH funded
Landry J, Catalano PJ, Staley C, Harris W, Hoffman J, Talamonti M, Xu N, Cooper H, Benson AB. Randomized Phase II Study of Gemcitabine Plus Radiotherapy Versus Gemcitabine, 5-Fluorouracil, and Cisplatin Followed by Radiotherapy and 5-Fluorouracil for Patients With Locally Advanced, Potentially Resectable Pancreatic Adenocarcinoma. Journal of surgical oncology. 2010 Jun;101(7):587-92.   PMCID: NIHMS351520
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term radiation-therapy

radiation-therapy chemotherapy trial cancer NCCN Guidelines carcinoma follow-up radiotherapy imrt concurrent radiation squamous-cell carcinoma radiation therapy melanoma randomized controlled-trial NCCN Clinical Practice Guidelines positron-emission-tomography randomized-trial phase-ii trial external-beam radiotherapy survival irradiation full-dose gemcitabine biochemical failure chemoradiation androgen deprivation localization phase-iii trial radical prostatectomy target volume soft tissue biopsy time trends twice-weekly gemcitabine germ-cell tumors women 70 years Brachytherapy conservative surgery preoperative chemoradiation pancreaticoduodenectomy mutations kit mutation gemcitabine endorectal mr long-term survival accelerated fractionation concurrent chemotherapy combination phase-ii 2007 doloff da-v5-ps1 growth risk pancreatic cancer implant radical prostatectomy prostate cancer-radiation therapy-androgen-deprivation therapy-prostate-specific antigen emission-tomography soft tissue extremity sarcoma factor receptor esophageal cancer Hodgkin disease concurrent capecitabine Hypoxia definitions 1987 arlson me-journal of chronic diseases-v40-p373 stem-cell transplantation united-states intensity-modulated radiotherapy neoadjuvant chemotherapy photon postoperative high-grade dysplasia 1993 wler wc-annals of thoracic surgery-v55-p986 solid tumors preoperative chemoradiation surgical adjuvant Prostate cancer antigen era taxol experience treatment international index trimodality postoperative radiotherapy neoadjuvant therapy gland adenocarcinoma long-term outcomes antigen doubling time lymphocyte predominance free survival surrogate end-point surgery gastrointestinal stromal tumors head and neck cancer toxicity survivors early breast-cancer primary extremity sarcoma Neoadjuvant therapy 2007 doloff da-v5-ps23 epidermal-growth-factor randomized clinical-trial comparing radical-mastectomy protein farnesyltransferase lymphoma comorbidity index pathology Eppendorf system paclitaxel pancreas cancer-gemcitabine-irradiation mortality study-group ghsg nocturnal penile tumescence hormonal-therapy cell lung-cancer Resectable pancreatic adenocarcinoma lymph-node dissection 1993 oy h-cancer-v71-p3774 stage-i seminoma dose-rate brachytherapy intraoperative combined Prostate magnetic resonance spectroscopy Magnetic resonance spectroscopy-Gold marker seeds androgen-deprivation therapy angiogenesis modality therapy men negative predictive-value accuracy european consensus blockade desmoid tumor consensus-group egcccg i-125 involved-field radiotherapy Biochemical failure induction chemotherapy of-function aromatase inhibitors 1989 ssa sd-international journal of radiation oncology biology physics-v16-p383 fine-needle-aspiration tumors adjuvant therapy deprivation mucosal melanoma cutaneous biopsy cores group protocol 92-02 prospective multicenter skull base oncology group rtog imatinib mesylate
Last updated on Friday, January 03, 2020